Drug intelligence / Profile preview

lutetium 177Lu meO-DOTA-7E11

Development stage: Phase 1
Lead developer: EUSA Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lutetium 177Lu meO-DOTA-7E11 is an experimental radiolabeled anti-PSMA monoclonal antibody conjugate in which the 7E11 antibody is chelated with meO-DOTA and labeled with the beta/gamma-emitting radionuclide lutetium-177, designed for targeted radioimmunotherapy and imaging of prostate cancer expressing prostate-specific membrane antigen (PSMA). Preclinical studies demonstrated preserved PSMA binding of the 7E11 conjugate, efficient Lu-177 radiolabeling, favorable pharmacokinetics with tumor uptake and retention in LNCaP xenografts, and acceptable acute toxicology in rodents and dogs. A phase I study (177Lu-CYT-500) was initiated to evaluate safety, tolerability, and dosing in patients with advanced prostate cancer.[2][5][8]

Other names: lutetium Lu-177 meO-DOTA-7E11lutetium-177 DOTA-7E11lutetium177 DOTA-7E11lutetium 177 DOTA-7E11177Lu-DOTA-7E11/CYT500

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on lutetium 177Lu meO-DOTA-7E11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium 177Lu meO-DOTA-7E11.

Explore the full profile